The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,505 | -26,892 | -6,008 | -12,640 |
| Depreciation | 332 | 378 | 427 | 881 |
| Deferred tax liability | - | 5 | - | - |
| Foreign exchange loss (gain) | -1,132 | 1,170 | -1,202 | 3,365 |
| Share-based compensation expense | 172 | 162 | 24 | 3,436 |
| Income tax receivable | - | -151 | -83 | 0 |
| Accrued interest receivable | -58 | -90 | -30 | -220 |
| Prepaid expenses and other current assets | 246 | -17 | -254 | 281 |
| Accounts payable | -678 | 492 | -385 | -795 |
| Accrued expenses | -4,283 | 3,896 | 12 | -222 |
| Income tax payable | 49 | -81 | 102 | 57 |
| Net cash used in operating activities | -8,969 | -22,952 | -4,259 | -12,709 |
| Purchase of property and equipment | 0 | 34 | 110 | 145 |
| Permit refund of construction in progress | 9 | - | - | - |
| Net cash provided by (used in) investing activities | 9 | -34 | -110 | -145 |
| Proceeds from issuance of common stock under stock option plan | - | - | 0 | 0 |
| Payment on convertible loan, third party | - | - | 0 | -10,000 |
| Payment on convertible loan-Related Party | 0 | -10,000 | - | - |
| Payment on convertible loan-Nonrelated Party | 0 | 0 | 0 | -250 |
| Net cash used in financing activities | 0 | 0 | 0 | -10,250 |
| Effect of foreign exchange rate on cash and cash equivalents | -1,132 | 1,170 | -1,202 | 3,365 |
| Net change in cash and cash equivalents | -10,092 | -21,816 | -5,571 | -19,739 |
| Cash and cash equivalents, beginning of period | 125,551 | 147,367 | 172,677 | - |
| Cash and cash equivalents, end of period | 115,459 | 125,551 | 147,367 | - |
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)